15,000 Shares in Axonics, Inc. (NASDAQ:AXNX) Purchased by Maven Securities LTD

Maven Securities LTD purchased a new stake in shares of Axonics, Inc. (NASDAQ:AXNX) in the 2nd quarter, Holdings Channel.com reports. The institutional investor purchased 15,000 shares of the company’s stock, valued at approximately $1,008,000.

Several other large investors have also bought and sold shares of the company. Edgestream Partners L.P. purchased a new stake in Axonics in the first quarter worth about $605,000. Janus Henderson Group PLC raised its holdings in shares of Axonics by 637.7% in the first quarter. Janus Henderson Group PLC now owns 178,322 shares of the company’s stock worth $12,298,000 after buying an additional 154,149 shares during the period. Gabelli Funds LLC bought a new stake in Axonics during the 1st quarter valued at about $12,271,000. Hsbc Holdings PLC grew its stake in Axonics by 26.5% in the fourth quarter. Hsbc Holdings PLC now owns 65,494 shares of the company’s stock worth $4,076,000 after purchasing an additional 13,734 shares in the last quarter. Finally, Tokio Marine Asset Management Co. Ltd. purchased a new stake in Axonics in the first quarter worth about $16,573,000. 99.48% of the stock is owned by hedge funds and other institutional investors.

Axonics Price Performance

AXNX opened at $69.41 on Wednesday. The business has a 50 day simple moving average of $68.85 and a 200-day simple moving average of $68.02. The stock has a market capitalization of $3.54 billion, a P/E ratio of -216.91 and a beta of 0.81. Axonics, Inc. has a 12 month low of $48.30 and a 12 month high of $69.91.

Axonics (NASDAQ:AXNX) last announced its quarterly earnings data on Thursday, August 1st. The company reported $0.13 earnings per share for the quarter, topping the consensus estimate of $0.10 by $0.03. Axonics had a negative net margin of 0.42% and a negative return on equity of 0.27%. The business had revenue of $114.57 million for the quarter, compared to analyst estimates of $112.83 million. During the same period in the prior year, the firm posted ($0.15) EPS. The company’s revenue was up 23.3% on a year-over-year basis. Research analysts anticipate that Axonics, Inc. will post 0.24 EPS for the current year.

Analysts Set New Price Targets

Separately, Needham & Company LLC reaffirmed a “hold” rating on shares of Axonics in a research report on Monday, August 5th. Eight investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $69.57.

About Axonics

Axonics, Inc, a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI.